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avenues and classification of CAA using a clinico-radiolog-
ical diagnostic framework.
Passive immunotherapy targeting amyloid‑beta 
reduces cerebral amyloid angiopathy and improves 
vascular reactivity
Accumulation of β amyloid in leptomeningeal vessels and 
cortical arterioles is the hallmark of cerebral amyloid angi-
opathy, this causes vessel stiffening, and vessel wall rup-
ture. Alzheimer’s disease amyloid plaques are composed 
of β-amyloid 42, whilst CAA results from accumulation 
of the β-amyloid 40, although β-amyloid 40 may migrate 
to the vasculature from parenchymal plaques. Recent work 
has shown that inefficient clearance of amyloid, rather than 
excess production is the primary contributor to β amyloid 
accumulation. Early work using a variety of approaches 
to increase clearance of β-amyloid, suggested a possible 
excess of micro-haemorrhages in animal models. A recent 
study from this group showed that chronic administration 
of high dose Ponezumab (a monoclonal antibody target-
ing β-amyloid) in an older group of transgenic mice did not 
increase micro-haemorrhage. This study tested the efficiency 
of β-amyloid clearance from the vasculature, and the conse-
quences of β-amyloid clearance on vascular reactivity.
Transgenic mice between 6 and 22 months were used. 
These were from a variety of strains—APP knock-in, com-
pound knock-in APP-PS1 and APP PSdE9 compound knock-
in animals. Multi-photon imaging used methoxy x-034 to 
label amyloid and pre-imaging rhodamine injection to 
track blood vessels. Animals were imaged on a monthly 
basis. The brains were then removed and lysed, using cen-
trifugation, the vascular tissue was separated from cortical 
regions and myelin. ELISA was used to measure β-amyloid 
Introduction
Cerebral amyloid angiopathy (CAA) is characterised by 
the build-up of β-amyloid in the lining of leptomeningeal 
and cortical arterioles and is responsible for cerebrovascu-
lar disease in the form of lobar intracerebral haemorrhage, 
microbleeds and superficial siderosis. As a result CAA has 
been thought of as an independent contributor affecting nor-
mal brain function and especially cognition in the elderly. 
Prominent cerebral amyloid angiopathy is often observed 
in the brains of elderly individuals and is almost univer-
sally found in patients with Alzheimer’s disease. Despite 
the prevalence of the condition and associated morbidity, 
no effective treatments exist for the non-inflammatory sub-
type. However, accurate diagnosis of clinical subtypes and 
knowledge of CAA’s contribution to Alzheimer’s pathology 
may allow the identification of novel treatment targets for 
CAA and Alzheimer’s.
Current research suggests a number of promising thera-
peutic avenues including reducing amyloid production, 
increasing rate of clearance of amyloid from blood vessels 
and reducing the toxic effects of amyloid on the blood ves-
sels. However, despite the apparent appropriateness of these 
approaches and a clear clinical need in an ageing population, 
clinical trials in CAA remain sparse.
This month’s journal club examines three articles on CAA 
exploring its role in cortical atrophy, potential treatment 
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quantitatively, whilst immunohistochemistry was used to 
study the distribution and number of vessels affected. Micro-
dialysis was employed to measure the burden of β-amyloid 
in the interstitial fluid. Cerebral vessels were exposed, and 
arteriolar responses to acetylcholine and hypercapnia was 
recorded by observers using a light microscope.
Immunohistochemistry showed a reduction in cerebrovas-
cular β-amyloid burden, as did the ELISA and multi-photon 
imaging. Parenchymal amyloid burden was unchanged. 
The microdialysis showed an increase in interstitial fluid 
β-amyloid, but not serum β-amyloid, following Ponezumab 
administration, suggesting a mobilisation of β-amyloid from 
the vasculature into the interstitial fluid as the mechanism 
of β-amyloid clearance. Finally, administration of Pon-
ezumab improved vascular reactivity to acetylcholine and 
hypercapnia.
Comments
This study extends the previous work, demonstrating an 
improvement in vascular reactivity and a reduction in cer-
ebral amyloid burden following Ponezumab administration. 
Furthermore, the work strongly suggests the mechanism of 
amyloid reduction, is by mobilising the interstitial fluid pool 
of β amyloid. However, the study was mechanistic: the treat-
ment was not compared with a control group, furthermore 
there were no assessments of cerebrovascular injury or cog-
nitive change, leaving unanswered questions over the clinical 
relevance of vascular β-amyloid clearance.
Bales KR et al. Brain (2016) 139; 563–577
Cortical atrophy in hereditary and sporadic forms 
of cerebral amyloid angiopathy: an observational 
case–control study
Cortical injury mediates the cognitive impairment of Alz-
heimer’s disease and other neurodegenerative disorders. 
Apparent cortical atrophy is often found in the brains of 
patients suffering from subcortical vascular injury. What 
is not clear is whether this atrophy is artefact from sul-
cal widening secondary to subcortical atrophy, or if there 
is both cortical and sub-cortical damage from small ves-
sel disease. CAA exerts its most significant effects at the 
subcortical level, causing micro-vascular damage and 
consequent ischaemia. Sporadic CAA is associated with 
subcortical vascular damage, but also parenchymal amy-
loid deposition: this dual pathology precludes assessment 
of subcortical vascular disease in isolation. This study 
recruited a group with a genetic form of CAA [heredi-
tary cerebral haemorrhage with amyloidosis—Dutch type 
(HCHWA-D)], to study the effects of subcortical vascular 
disease on cortical thickness. Cortical thickness was also 
assessed in a group with sporadic CAA, Alzheimer’s dis-
ease and a control group. Further imaging measures were 
taken to delineate the relationship between micro-vascular 
disease, vascular reactivity and cortical thickness.
Genetically confirmed subjects carrying the mutation 
in codon 693 of the amyloid precursor protein gene were 
recruited from Leiden University and Massachusetts Gen-
eral Hospital. 26 subjects with HCHWA-D were recruited 
and compared with 28 age-matched controls in Leiden, 
in addition to 63 non-demented patients with CAA, 189 
healthy controls and 63 patients with Alzheimer’s disease 
from the US centre. Freesurfer cortical parcellation soft-
ware was used to measure cortical thickness on images 
derived from FLAIR and T1 MPRAGE sequences. BOLD 
sequences during a standardised visual stimulus were used 
to assess vascular reactivity. All images were derived on 
3T machines.
HCHWA-D subjects had thinner cortices than healthy 
controls, but hippocampal volume did not differ between 
the groups. Patients with sporadic CAA also had more 
marked cortical thinning when compared with a control 
group, particularly in the occipital, temporal, posterior 
parietal and medial frontal regions. These results were 
robust even when CAA patients with lobar haemor-
rhage were excluded. The Alzheimer’s disease group had 
more marked cortical thinning and hippocampal volume 
loss than the healthy controls and the CAA group. The 
BOLD measures correlated with cortical thickness in the 
HCHWA-D group, and remained significant even after 
adjusting for demographic variables, white matter disease, 
haemorrhage and microbleeds. Furthermore, the vascular 
reactivity measure mediated the case status relationship 
with cortical thinning: when vascular reactivity was added 
to the statistical model, case status became non-significant, 
demonstrating that vascular reactivity mediates the corti-
cal thinning seen in the HCHWA-D subjects.
Comments
The unique disease model of a purely vasculopathic form 
of CAA used in this elegant study has provided evidence 
of cortical thinning independent of Alzheimer pathology, 
and supports the hypothesis that vascular amyloid is an 
independent contributor to cortical atrophy. Furthermore, 
these findings are generalisable to sporadic CAA. This 
study lends support to the suggestion that CAA and small 
vessel disease is an important contributory factor in age-
associated cognitive impairment and suggests a potentially 
modifiable pathway for future therapeutic research.
Fotiadis P et al. Lancet Neurol. (2016); 15(8): 811–81
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Validation of clinico‑radiological criteria 
for the diagnosis of cerebral amyloid angiopathy: 
related inflammation
Cerebral amyloid angiitis (CAAri) is an inflammatory vari-
ant of CAA that responds to immunosuppressive therapy. 
Unfortunately proving the diagnosis often necessitates brain 
biopsy which carries a risk of significant morbidity and mor-
tality. This study assessed the sensitivity and specificity of 
pre-specified clinico-radiological criteria for diagnosis of 
CAAri in a group of biopsy proven CAAri and CAA, to see 
if brain biopsy may be avoided in selected patients.
The criteria were: (1) clinical presentation with headache, 
altered consciousness, neuropsychiatric abnormalities, focal 
deficits and seizures, (2) patchy, confluent, subcortical T2/
FLAIR lesions without meningeal involvement, (3) multi-
ple micro-haemorrhages or superficial siderosis, and prior 
lobar haemorrhage, (4) absence of any other cause. ‘Prob-
able CAAri’ cases had asymmetrical white matter change, 
whilst ‘Possible CAAri’ cases only required subcortical 
white matter change. The medical records of patients admit-
ted to Massachusetts General Hospital between 1995 and 
2013 were reviewed for a diagnosis of biopsy proven CAAri. 
22 cases were found, 7 were excluded, as they did not have 
the relevant MR sequences. 2 further cases were identified 
from a biomarker study. The cases were compared with 37 
controls who had a brain biopsy and who satisfied the Bos-
ton criteria for CAA. The control group was subdivided into 
those with (21) and without (16) intracerebral haemorrhage. 
Imaging was reviewed by a neurologist blind to case–control 
status, scans were reviewed by a second neurologist to verify 
accuracy.
The inter-rater reliability of the imaging rating was 
high (Ҡ 0.8). In the CAAri group 82% met the criteria 
for ‘Probable CAAri’ and ‘Possible CAAri’, in the con-
trol group with lobar haemorrhage, 5% met the ‘Possible 
CAAri’ and none met the ‘Probable CAAri’ criteria. The 
control group without haemorrhage, had a higher percent-
age of cases meeting criteria for Possible CAAri (69%) and 
1 case met the ‘Probable CAAri’ criteria. The criteria had 
an overall sensitivity of 82% and specificity of 68%. Diffu-
sion weighted imaging and contrast-enhanced imaging did 
not significantly differ between the groups. Intriguingly the 
control participant rated as ‘Probable CAAri’ was given high 
dose steroids and improved markedly, raising the possibility 
his brain biopsy may have missed the inflammatory region.
Comments
The authors identify limitations in the retrospective design 
of the study and small case numbers. As a result, the classifi-
cation system proposed may not be yet ready for general use, 
but the data presented suggests that in CAA patients with 
lobar haemorrhage a reliable diagnosis of CAA-ri might be 
reached from basic clinical and magnetic resonance imaging 
information alone. However, in those without haemorrhage, 
these criteria may not be so reliable. Furthermore a case 
could be made for the empirical use of immunosuppression 
without brain biopsy in selected patients.
Auriel E et al. JAMA Neurol. (2016);73(2):197–202
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